Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Growblox Sciences Inc (GBLX)

Growblox Sciences Inc (GBLX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.40
Trade GBLX with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0450 +11.11%
on 07/15/21
0.0630 -20.63%
on 06/29/21
+0.0011 (+2.25%)
since 06/23/21
3-Month
0.0335 +49.25%
on 05/12/21
0.0694 -27.95%
on 06/09/21
-0.0001 (-0.20%)
since 04/23/21
52-Week
0.0200 +150.00%
on 10/23/20
0.1325 -62.26%
on 02/16/21
+0.0190 (+61.29%)
since 07/23/20

Most Recent Stories

More News
GB Sciences Using AI Technology in Plant-Based Drug Discovery Research

Biotech innovator GB Sciences has launched a drug discovery platform using AI technology that can identify and predict the efficacy of combinations of novel active ingredients from plants.

GBLX : 0.0500 (-6.54%)
Gary Herman Joins GB Sciences' Subsidiary GbS Global Biopharma as Advisory Director

LAS VEGAS / ACCESSWIRE / June 22, 2021 / (OTCQB:GBLX) announces that long-term investor Gary Herman has joined GbS Global Biopharma, Inc., its wholly owned Canadian subsidiary, as an Advisory Director....

GBLX : 0.0500 (-6.54%)
GB Sciences' Board of Directors Has Passed a Unanimous Written Consent Promoting Dr. Andrea Small-Howard to the Role of President

The UWC also retains John Poss as Chairman and CEO of GB Sciences, Inc.

GBLX : 0.0500 (-6.54%)
GB Sciences Featured & Speaking at the SACHS Associates' 4th Annual Neuroscience Innovation Forum

LAS VEGAS, NV / ACCESSWIRE / April 27, 2021 / (OTCQB:GBLX), a leading phytomedicine research and biopharmaceutical development company, will be featured during the SPOTLIGHT SHOWCASE at the for Business...

GBLX : 0.0500 (-6.54%)
GB Sciences and Purisys Announce Preferred Supplier Relationship to Advance Cannabinoid-Containing Pharmaceuticals

Purisys will supply ultra-high purity cannabinoids for use in GB Sciences' cannabinoid-containing, optimized therapeutic mixtures (OTM).

GBLX : 0.0500 (-6.54%)
GB Sciences Files Provisional Patent Application to Protect Its Proprietary Drug Discovery Platform

GBS' newest proprietary drug discovery platform uses data analytics and machine learning to gain valuable predictive insights into the likely efficacy of novel plant-derived therapeutics. This unique ability...

GBLX : 0.0500 (-6.54%)
GB Sciences Publishes Study on Creation of Novel Terpene-Containing Nanoparticles for Pain Relief

LAS VEGAS, NV / ACCESSWIRE / March 23, 2021 / , Inc. (OTCQB:GBLX) and its Spanish research partners at the Universidad de Sevilla (USE) are pleased to announce the publication of a new scientific paper...

GBLX : 0.0500 (-6.54%)
GB Sciences Begins Proof of Concept Studies with Michigan State University for the Treatment of Cytokine Release Syndrome

LAS VEGAS, NV / ACCESSWIRE / January 25, 2021 / (OTCQB:GBLX), through GBS Global Biopharma, Inc. ("GBS"), has executed a Sponsored Research Agreement with Michigan State University (MSU) to obtain valuable...

GBLX : 0.0500 (-6.54%)
GB Sciences Receives $4,150,000 and Completes the Sale of Its Louisiana Operations to Wellcana Plus

LAS VEGAS, NV / ACCESSWIRE / January 12, 2021 / (OTCQB:) completed the sale of its remaining interest in GB Sciences Louisiana LLC ("GBSLA") on December 16, 2020.

GBLX : 0.0500 (-6.54%)
GB Sciences Announces Issuance of US Patent for its Proprietary, Cannabinoid-Based Anti-Inflammatory Formulations

LAS VEGAS / ACCESSWIRE / December 8, 2020 / GB Sciences, Inc. (OTCQB:GBLX) announced that the United States Patent and Trademark Office (USPTO) will issue U.S. Patent No. 10,857,107 entitled "Cannabinoid-Containing...

GBLX : 0.0500 (-6.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Key Turning Points

3rd Resistance Point 0.0568
2nd Resistance Point 0.0554
1st Resistance Point 0.0527
Last Price 0.0500
1st Support Level 0.0486
2nd Support Level 0.0472
3rd Support Level 0.0445

See More

52-Week High 0.1325
Fibonacci 61.8% 0.0895
Fibonacci 50% 0.0762
Fibonacci 38.2% 0.0630
Last Price 0.0500
52-Week Low 0.0200

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar